HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Culleton, B. Search for Related Content PubMed Articles by Culleton, B.

Intensified blood pressure (BP) control was not better than conventional BP control in non-diabetic chronic renal disease

Clinical impact ratings Nephrology

Key Words: antihypertensive agents • felodipine • kidney diseases

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial (Ramipril Efficacy In Nephropathy [REIN] 2 trial).

Allocation: concealed.^*

Blinding: unblinded.^*

Follow up period: median 19 months (total follow up period 36 mo).

Setting: 29 centres in Bulgaria, Italy, Spain, and Switzerland.

Patients: 338 patients (age range 18–70 years) with non-diabetic nephropathy and persistent proteinuria (ie, a proteinuria of 1–3 g/d and creatinine clearance <45 ml/min per 1.73 m², or proteinuria 3 g/d and creatinine clearance <70 ml/min per 1.73 m²) who had not received angiotensin converting enzyme (ACE) inhibition treatment for 6 weeks. Exclusion criteria included use of corticosteroids, non-steroidal anti-inflammatory drugs, or immunosuppressive drugs; and acute myocardial infarction or cerebrovascular accident in previous 6 months.

Intervention: intensified BP control (<130 mm Hg systolic and <80 mm Hg diastolic) (n = 169) or conventional BP control (<90 mm Hg diastolic irrespective of systolic BP) (n = 169). Patients in the intensified BP control . . . [Full text of this article]

Bruce Culleton, MD, FRCPC

University of Calgary
Calgary, Alberta, Canada